asenapine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychoactive 4115 65576-45-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • Org-5222
  • Org 5222
  • asenapine
  • saphris
  • asenapine maleate
  • sycrest
  • Molecular weight: 285.77
  • Formula: C17H16ClNO
  • CLOGP: 4.28
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -3.96
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.71 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
S (Water solubility) 3.70 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Aug. 13, 2009 FDA FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anosognosia 1260.76 33.07 241 9314 2955 63476512
Blood prolactin abnormal 1257.18 33.07 239 9316 2840 63476627
Disturbance in social behaviour 1201.20 33.07 240 9315 3753 63475714
Sexual dysfunction 1174.28 33.07 239 9316 4120 63475347
Metabolic disorder 1073.47 33.07 238 9317 6265 63473202
Dystonia 1020.44 33.07 264 9291 13555 63465912
Personality change 1002.66 33.07 228 9327 6745 63472722
Sedation 911.99 33.07 305 9250 38504 63440963
Dyskinesia 858.23 33.07 278 9277 31724 63447743
Suicide attempt 635.70 33.07 264 9291 60654 63418813
Blood glucose increased 551.93 33.07 263 9292 83493 63395974
Inappropriate schedule of product administration 492.35 33.07 261 9294 103704 63375763
Hypoaesthesia oral 430.68 33.07 133 9422 12900 63466567
Underdose 415.79 33.07 156 9399 27300 63452167
Incorrect route of product administration 262.33 33.07 112 9443 27340 63452127
Akathisia 258.97 33.07 83 9472 9063 63470404
Insurance issue 166.91 33.07 54 9501 6067 63473400
Dysgeusia 129.23 33.07 83 9472 46627 63432840
Swollen tongue 114.35 33.07 69 9486 34731 63444736
Mania 97.13 33.07 44 9511 12323 63467144
Adverse drug reaction 93.71 33.07 85 9470 79629 63399838
Condition aggravated 85.30 33.07 187 9368 402030 63077437
Tooth discolouration 83.56 33.07 21 9534 947 63478520
Personality change due to a general medical condition 83.38 33.07 16 9539 198 63479269
Weight increased 76.55 33.07 139 9416 260653 63218814
Tardive dyskinesia 75.58 33.07 33 9522 8469 63470998
Extrapyramidal disorder 73.04 33.07 37 9518 13247 63466220
Suicidal ideation 62.65 33.07 61 9494 62360 63417107
Completed suicide 62.13 33.07 92 9463 145581 63333886
Diarrhoea 57.89 33.07 18 9537 715348 62764119
Restless legs syndrome 56.38 33.07 35 9520 18496 63460971
Fatigue 55.03 33.07 33 9522 887995 62591472
Drug ineffective 54.14 33.07 303 9252 1044462 62435005
Oral discomfort 51.66 33.07 26 9529 9175 63470292
Oropharyngeal blistering 50.94 33.07 14 9541 895 63478572
Tongue blistering 47.28 33.07 15 9540 1580 63477887
Arthralgia 44.86 33.07 15 9540 569695 62909772
Pain 43.78 33.07 29 9526 740599 62738868
Somnolence 43.41 33.07 88 9467 178597 63300870
Agitation 38.14 33.07 46 9509 59711 63419756
Asthenia 34.05 33.07 8 9547 383596 63095871

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicide attempt 507.57 35.88 211 6368 38905 34911447
Akathisia 464.04 35.88 133 6446 7976 34942376
Antipsychotic drug level below therapeutic 387.51 35.88 91 6488 2456 34947896
Sedation 382.79 35.88 145 6434 20861 34929491
Therapeutic product effect variable 374.96 35.88 88 6491 2368 34947984
Disinhibition 371.16 35.88 92 6487 3134 34947218
Anosognosia 364.72 35.88 73 6506 900 34949452
Obsessive-compulsive disorder 344.03 35.88 97 6482 5467 34944885
Blood prolactin abnormal 335.18 35.88 68 6511 901 34949451
Increased appetite 324.86 35.88 99 6480 7330 34943022
Euphoric mood 320.19 35.88 92 6487 5549 34944803
Disturbance in social behaviour 291.33 35.88 68 6511 1783 34948569
Dystonia 280.27 35.88 97 6482 10748 34939604
Sexual dysfunction 241.77 35.88 76 6503 6227 34944125
Metabolic disorder 239.19 35.88 69 6510 4214 34946138
Emotional poverty 201.06 35.88 41 6538 557 34949795
Dyskinesia 199.49 35.88 93 6486 22320 34928032
Personality change 180.66 35.88 58 6521 5081 34945271
Weight increased 159.31 35.88 135 6444 92898 34857454
Therapeutic product effect incomplete 147.77 35.88 101 6478 50440 34899912
Inappropriate schedule of product administration 146.48 35.88 109 6470 62187 34888165
Leukaemia 145.74 35.88 48 6531 4555 34945797
Dyslipidaemia 119.40 35.88 47 6532 7441 34942911
Leukopenia 111.10 35.88 93 6486 62763 34887589
Extrapyramidal disorder 106.97 35.88 51 6528 12829 34937523
Hypoaesthesia oral 105.95 35.88 37 6542 4192 34946160
Underdose 103.69 35.88 51 6528 13729 34936623
Prescribed overdose 103.45 35.88 47 6532 10600 34939752
Obesity 97.91 35.88 48 6531 12830 34937522
Blood glucose increased 90.51 35.88 85 6494 66633 34883719
Drug ineffective 90.05 35.88 236 6343 456515 34493837
Toxicity to various agents 80.83 35.88 139 6440 200223 34750129
Incorrect route of product administration 80.22 35.88 44 6535 14801 34935551
Head titubation 80.20 35.88 18 6561 393 34949959
Cogwheel rigidity 76.40 35.88 22 6557 1330 34949022
Suicidal ideation 69.71 35.88 59 6520 40329 34910023
Mania 65.04 35.88 33 6546 9478 34940874
Sedation complication 62.19 35.88 20 6559 1757 34948595
Hallucination, auditory 55.37 35.88 32 6547 11885 34938467
Irritability 55.22 35.88 42 6537 24648 34925704
Schizoaffective disorder 55.02 35.88 17 6562 1310 34949042
Dysgeusia 54.74 35.88 43 6536 26454 34923898
Swollen tongue 51.84 35.88 33 6546 14572 34935780
Anticholinergic syndrome 43.25 35.88 14 6565 1255 34949097
Therapy non-responder 38.56 35.88 42 6537 39104 34911248
Insurance issue 36.75 35.88 14 6565 2025 34948327

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anosognosia 1487.47 28.88 282 11132 3482 79729492
Blood prolactin abnormal 1449.42 28.88 274 11140 3327 79729647
Disturbance in social behaviour 1367.30 28.88 275 11139 4695 79728279
Sexual dysfunction 1283.90 28.88 282 11132 7481 79725493
Metabolic disorder 1199.45 28.88 275 11139 8895 79724079
Dystonia 1119.28 28.88 308 11106 21091 79711883
Personality change 1118.66 28.88 265 11149 9905 79723069
Sedation 1101.15 28.88 373 11041 51522 79681452
Dyskinesia 965.87 28.88 326 11088 44447 79688527
Suicide attempt 916.69 28.88 369 11045 82563 79650411
Blood glucose increased 579.24 28.88 296 11118 114679 79618295
Inappropriate schedule of product administration 419.27 28.88 252 11162 133376 79599598
Underdose 319.14 28.88 134 11280 33017 79699957
Akathisia 306.74 28.88 102 11312 13157 79719817
Hypoaesthesia oral 277.01 28.88 96 11318 14028 79718946
Insurance issue 202.81 28.88 61 11353 5672 79727302
Emotional poverty 173.16 28.88 37 11377 850 79732124
Incorrect route of product administration 155.46 28.88 83 11331 34846 79698128
Adverse drug reaction 145.22 28.88 100 11314 66292 79666682
Drug ineffective 136.39 28.88 399 11015 1080514 78652460
Mania 103.24 28.88 51 11363 18209 79714765
Antipsychotic drug level below therapeutic 98.94 28.88 25 11389 1213 79731761
Increased appetite 97.34 28.88 43 11371 11935 79721039
Condition aggravated 95.89 28.88 217 11197 500907 79232067
Swollen tongue 95.12 28.88 65 11349 42505 79690469
Suicidal ideation 90.40 28.88 80 11334 76260 79656714
Extrapyramidal disorder 90.07 28.88 50 11364 22629 79710345
Therapeutic product effect variable 86.95 28.88 25 11389 1984 79730990
Disinhibition 84.83 28.88 26 11388 2572 79730402
Dysgeusia 75.95 28.88 64 11350 57113 79675861
Obsessive-compulsive disorder 70.79 28.88 28 11386 5899 79727075
Personality change due to a general medical condition 70.07 28.88 14 11400 228 79732746
Euphoric mood 60.41 28.88 27 11387 7699 79725275
Neuroleptic malignant syndrome 59.00 28.88 41 11373 27518 79705456
Tardive dyskinesia 58.19 28.88 29 11385 10542 79722432
Weight increased 57.23 28.88 124 11290 277262 79455712
Diarrhoea 56.33 28.88 28 11386 880461 78852513
Parkinsonism 56.27 28.88 33 11381 16551 79716423
Hallucination, auditory 51.98 28.88 34 11380 20659 79712315
Irritability 50.44 28.88 44 11370 41100 79691874
Dyslipidaemia 49.92 28.88 27 11387 11606 79721368
Completed suicide 48.56 28.88 108 11306 245659 79487315
Pneumonia 46.91 28.88 18 11396 660228 79072746
Fatigue 46.60 28.88 39 11375 929688 78803286
Anaemia 46.12 28.88 5 11409 445010 79287964
Arthralgia 41.59 28.88 15 11399 571788 79161186
Agitation 40.53 28.88 60 11354 99655 79633319
Schizoaffective disorder 39.75 28.88 14 11400 2138 79730836
Tooth discolouration 39.57 28.88 12 11402 1145 79731829
Cogwheel rigidity 34.83 28.88 14 11400 3074 79729900
Abdominal pain 34.34 28.88 7 11407 389562 79343412
Cataplexy 33.29 28.88 10 11404 924 79732050
Head titubation 33.24 28.88 10 11404 928 79732046
Product solubility abnormal 32.89 28.88 10 11404 962 79732012
Somnolence 32.39 28.88 91 11323 238890 79494084
Pharyngeal hypoaesthesia 32.05 28.88 8 11406 369 79732605
Oral discomfort 32.00 28.88 19 11395 9741 79723233
Drooling 31.83 28.88 16 11398 5918 79727056
Pain 31.11 28.88 33 11381 703769 79029205
Paranoia 30.52 28.88 24 11390 19408 79713566

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AH05 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Diazepines, oxazepines, thiazepines and oxepines
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35471 psychotropic drugs
CHEBI has role CHEBI:35530 beta-adrenergic blockers
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:65191 atypical antipsychotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar affective disorder, current episode manic indication 191618007
Depression Treatment Adjunct off-label use
Suicidal thoughts contraindication 6471006
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Agranulocytosis contraindication 17182001 DOID:12987
Lowered convulsive threshold contraindication 19260006
Myocardial infarction contraindication 22298006 DOID:5844
Alzheimer's disease contraindication 26929004 DOID:10652
Hypovolemia contraindication 28560003
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Dehydration contraindication 34095006
Dysphagia contraindication 40739000
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Leukopenia contraindication 84828003 DOID:615
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Hypomagnesemia contraindication 190855004
Cerebrovascular accident contraindication 230690007
Hyperprolactinemia contraindication 237662005 DOID:12700
Transient ischemic attack contraindication 266257000 DOID:224
Esophageal dysmotility contraindication 266434009 DOID:9192
Syncope contraindication 271594007
Neutropenic disorder contraindication 303011007 DOID:1227
Senile dementia with psychosis contraindication 371026009
At risk for aspiration contraindication 371736008
Impaired cognition contraindication 386806002
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.13 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
EQ 2.5MG BASE SAPHRIS ALLERGAN N022117 March 12, 2015 RX TABLET SUBLINGUAL 7741358 April 6, 2026 METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
EQ 2.5MG BASE SAPHRIS ALLERGAN N022117 March 12, 2015 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
3.8MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10583121 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
3.8MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10814002 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
5.7MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10583121 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
5.7MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10814002 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
7.6MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10583121 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
7.6MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10814002 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.61 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.75 WOMBAT-PK CHEMBL
D(1A) dopamine receptor GPCR Ki 8.70 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 8.19 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 7.97 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 9.80 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 9.93 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 9.22 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 9.47 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8.92 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 8.73 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 9.06 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 7.64 PDSP
Histamine H1 receptor GPCR Ki 9 WOMBAT-PK
Histamine H2 receptor GPCR IC50 8.21 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 6.11 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 6.04 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5.49 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 6.57 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 8.40 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.40 IUPHAR
Alpha-2C adrenergic receptor GPCR Ki 7.89 PDSP
Sodium-dependent dopamine transporter Transporter Ki 5.50 PDSP
D(4) dopamine receptor GPCR Ki 8.71 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.35 PDSP
Alpha-1B adrenergic receptor GPCR Ki 8.41 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 8.60 WOMBAT-PK
Beta-1 adrenergic receptor GPCR Ki 5.30 PDSP
5-hydroxytryptamine receptor 1E GPCR AGONIST Ki 8 IUPHAR
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP

External reference:

IDSource
4029058 VUID
N0000179817 NUI
D02995 KEGG_DRUG
85650-56-2 SECONDARY_CAS_RN
4029058 VANDF
C2000088 UMLSCUI
CHEBI:71253 CHEBI
CHEMBL3187365 ChEMBL_ID
CHEMBL3544974 ChEMBL_ID
DB06216 DRUGBANK_ID
C522667 MESH_SUPPLEMENTAL_RECORD_UI
163091 PUBCHEM_CID
22 IUPHAR_LIGAND_ID
8278 INN_ID
JKZ19V908O UNII
784649 RXNORM
167374 MMSL
26689 MMSL
341671 MMSL
d07473 MMSL
013233 NDDF
013234 NDDF
443374004 SNOMEDCT_US
443375003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0052-0118 TABLET 5 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0052-0119 TABLET 10 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0052-2139 TABLET 5 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0052-2142 TABLET 10 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2402 TABLET 2.50 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2402 TABLET 2.50 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2402 TABLET 2.50 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2405 TABLET 5 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2405 TABLET 5 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2405 TABLET 5 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2410 TABLET 10 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2410 TABLET 10 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2410 TABLET 10 mg SUBLINGUAL NDA 36 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 16590-936 TABLET 10 mg SUBLINGUAL NDA 34 sections
ASENAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42794-016 TABLET 5 mg SUBLINGUAL ANDA 21 sections
ASENAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42794-016 TABLET 5 mg SUBLINGUAL ANDA 21 sections
ASENAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42794-017 TABLET 10 mg SUBLINGUAL ANDA 21 sections
ASENAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42794-017 TABLET 10 mg SUBLINGUAL ANDA 21 sections
Asenapine Human Prescription Drug Label 1 46708-198 TABLET 5 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 46708-198 TABLET 5 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 46708-199 TABLET 10 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 46708-199 TABLET 10 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 46708-544 TABLET 2.50 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 46708-544 TABLET 2.50 mg SUBLINGUAL ANDA 29 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-358 TABLET 5 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-359 TABLET 5 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-360 TABLET 10 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-361 TABLET 10 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-928 TABLET 2.50 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 59762-1091 TABLET 2.50 mg SUBLINGUAL NDA AUTHORIZED GENERIC 35 sections